Mega Lifesciences (MEGA) Aandelenoverzicht
Mega Lifesciences Public Company Limited, samen met haar dochterondernemingen, produceert en verkoopt voedingssupplementen, voorgeschreven farmaceutische producten, receptvrije producten, kruidenproducten, vitamines en fast moving consumer goods in Zuidoost-Azië en Afrika bezuiden de Sahara. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
MEGA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mega Lifesciences Public Company Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ฿34.75 |
| 52 Week Hoogtepunt | ฿40.00 |
| 52 Week Laag | ฿24.30 |
| Bèta | 0.33 |
| 1 maand verandering | 4.51% |
| 3 maanden verandering | -9.74% |
| 1 Jaar Verandering | 39.00% |
| 3 jaar verandering | -10.90% |
| 5 jaar verandering | -4.14% |
| Verandering sinds IPO | 63.15% |
Recent nieuws en updates
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Recent updates
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.Rendement voor aandeelhouders
| MEGA | TH Pharmaceuticals | TH Markt | |
|---|---|---|---|
| 7D | -1.4% | -1.6% | 1.4% |
| 1Y | 39.0% | 5.9% | 31.9% |
Rendement versus industrie: MEGA overtrof de TH Pharmaceuticals industrie, die het afgelopen jaar een rendement 5.9 % opleverde.
Rendement versus markt: MEGA overtrof de TH markt, die het afgelopen jaar een rendement opleverde van 31.9 %.
Prijsvolatiliteit
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TH Market | 10.3% |
| 10% least volatile stocks in TH Market | 2.6% |
Stabiele aandelenkoers: MEGA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de TH markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van MEGA is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
Mega Lifesciences Public Company Limited, samen met haar dochterondernemingen, produceert en verkoopt voedingssupplementen, voorgeschreven farmaceutische producten, receptvrije producten, kruidenproducten, vitaminen en fast moving consumer goods in Zuidoost-Azië en Afrika bezuiden de Sahara. Het bedrijf is actief in drie segmenten: Merken, Distributie en Original Equipment Manufacture (OEM). Het levert verschillende geneesmiddelen voor allergieën; bloedsomloop en geheugen; botten en gewrichten; lever en spijsvertering; diabetici; oog-, hart- en huidverzorging; pijn, slaap, welzijn, kruiden en hoest en verkoudheid; en vitaminen, probiotica, medische en sportvoeding, evenals verzorgingsproducten voor kinderen, mannen en vrouwen.
Mega Lifesciences Public Company Limited Samenvatting
| MEGA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ฿30.30b |
| Inkomsten(TTM) | ฿2.07b |
| Inkomsten(TTM) | ฿14.63b |
Is MEGA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MEGA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ฿14.63b |
| Kosten van inkomsten | ฿6.94b |
| Brutowinst | ฿7.69b |
| Overige uitgaven | ฿5.62b |
| Inkomsten | ฿2.07b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
May 28, 2026
| Winst per aandeel (EPS) | 2.37 |
| Brutomarge | 52.55% |
| Nettowinstmarge | 14.13% |
| Schuld/Eigen Vermogen Verhouding | 4.6% |
Hoe presteerde MEGA op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 22:07 |
| Aandelenkoers aan het einde van de dag | 2026/05/25 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Mega Lifesciences Public Company Limited wordt gevolgd door 16 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |